A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients with Bullous Pemphigoid
This research study is for adults with a skin condition called Bullous Pemphigoid. It's designed to see if a new medicine, Dupixent, can help improve the rash, blisters, and severe itching that come with this condition. Participants will receive either Dupixent, a standard steroid treatment (Prednisolone), or a placebo (a dummy medicine). We will compare how well Dupixent works against these other options in helping patients achieve clear skin without needing strong steroids. The study will also carefully check for any side effects. The goal is to find a safer and more effective way to manage Bullous Pemphigoid.
At a glance
What is this study about?
You're probably here because you're interested in a new treatment for Bullous Pemphigoid, a skin condition that causes painful blisters and severe itching. This study is an important step in finding better ways to help people like you. Doctors are testing a medicine called Dupixent (which you might know as dupilumab) to see if it can improve this condition.
Bullous Pemphigoid is an autoimmune disease, meaning your body's immune system mistakenly attacks healthy skin. This leads to those uncomfortable blisters and a lot of itching. Currently, treatments often involve strong steroids like Prednisolone, which can have side effects when used for a long time. This study aims to find out if Dupixent can not only clear up the skin but also allow people to use fewer steroids, making treatment more comfortable and safer.
The researchers will be looking to see if Dupixent helps people achieve 'sustained remission,' which means their skin clears up and stays clear for a good amount of time. They'll also be tracking how much itching is reduced, how the blisters improve, and generally how much better people feel in their daily lives. Safety is a top priority, so any side effects will be closely monitored throughout the study.
Key takeaways
- This study tests Dupixent for adults with Bullous Pemphigoid.
- It compares Dupixent to standard steroids and a dummy treatment.
- The main goal is to see if Dupixent helps clear skin and reduces itching.
- Researchers will also track reducing steroid use and safety.
- It's a 'blinded' study, meaning you won't know which treatment you get.
Who may be eligible?
To join this study, you need to be an adult, at least 18 years old, and have been diagnosed with Bullous Pemphigoid. Both men and women are welcome to take part.
There might be specific medical criteria that determine if this study is right for you, for example, certain other health conditions you might have, or medicines you might be taking. The study doctors will carefully review your medical history to make sure it's safe and appropriate for you to participate.
It's important to remember that not everyone with Bullous Pemphigoid will be able to join. These criteria help ensure the study is safe for participants and that the results are clear and reliable. Your doctor can help you understand if you meet the specific requirements.
- Are you 18 years old or older?
- Have you been diagnosed with Bullous Pemphigoid?
- Are you able to attend regular clinic visits?
- Are you willing to potentially receive either an active drug or a placebo?
This is a guide only — the research team will confirm whether you can take part.
What does participation involve?
If you join this study, you'll be assigned by chance to one of three groups. You might receive Dupixent, a common steroid medicine called Prednisolone, or a placebo (a dummy medicine that looks like Dupixent but has no active drug). You won't know which treatment you're getting, and neither will your study doctor – this helps make the study fair and accurate. You'll take the medicine regularly, likely through injections for Dupixent or the placebo, and tablets for Prednisolone.
Over several months, you'll have regular visits to the study clinic. During these visits, doctors and nurses will closely monitor your skin condition, including your blisters, rash, and how much itching you have. They'll also assess your overall health, ask about any side effects, and take blood samples. These checks help the research team understand how well the treatment is working and if it's safe. The exact number of visits and the total duration will be explained in detail before you decide to join.
Potential risks and benefits
Locations (4)
- —France
- —Poland
- —Germany
- —Spain
Common questions
What is Bullous Pemphigoid?
It's a rare skin condition that causes itchy rashes and large blisters, usually on the arms, legs, and belly.
What is Dupixent?
Dupixent is a medicine that works by calming down parts of your immune system that cause inflammation, potentially helping with blister conditions like Bullous Pemphigoid.
What does 'placebo-controlled' mean?
It means some people will get the active medicine, and others will get a 'dummy' medicine (placebo) that looks the same but has no drug in it. This helps researchers see if the real medicine actually works.
Will I know if I'm getting the real medicine or the placebo?
No, neither you nor your study doctor will know which treatment you are receiving until after the study is complete. This helps keep the results fair.
What are 'side effects'?
Side effects are unwanted or unexpected reactions to a medicine. The study will carefully record all side effects to understand the medicine's safety.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.